Clinical Trial Update: Open Label Continuation Study in Moderate to Severe Psoriasis [Phase 3]

View source ↗

Summary

This clinical trial update notes that the open-label continuation Phase 3 study in moderate to severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Moderate to Severe Plaque Psoriasis | Phase 3 | Status: COMPLETED